title: Neuroleptic properties of the ion-channel-forming peptaibol zervamicin: locomotor activity and behavioral effects.
abstract: Zervamicins IIA and IIB are members of the peptaibol family of peptide antibiotics. They are produced by the fungus Emericellopsis salmosynnemata. Peptaibols are known to be of potential usefulness for chemotherapeutic applications, as are other secondary fungal metabolites. Previously, we have found zervamicins to decrease spontaneous locomotor activity in mice, suggesting their neurotropic properties on an equal footing with antimicrobial activity. The current study deals with behavioral effects of zervamicins IIA and IIB in mice. According to our results, both zervamicins induce a reliable decrease in locomotion and exploratory activity measured in the hole-board test. The behavioral effects of zervamicin IIA become apparent at lower dosages (0.05-2.0 mg/kg) as compared with zervamicin IIB (0.5-12.0 mg/kg). The experiments on behavioral effects in the elevated plus maze test showed that both zervamicins caused a reliable decrease in the number of head-dippings, open-arm entries, and rearings. The observed behavioral effects may be rather associated with a decrease in the exploratory activity than with anxiety-related responses in mice. Zervamicins induced depression-like behavior of experimental animals in the forced-swim test. Both peptaibols reduce physical endurance and change motor coordination of experimental animals in the bar-holding test. Taken together, the data obtained clearly indicate that both zervamicins possess neuroleptic activity.
authors.affiliation: Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation. ovch@ibch.ru
authors.forename: Tatiana V
authors.initials: TV
authors.lastname: Ovchinnikova
authors.forename: Natalia G
authors.initials: NG
authors.lastname: Levitskaya
authors.forename: Olga G
authors.initials: OG
authors.lastname: Voskresenskaya
authors.forename: Zoya A
authors.initials: ZA
authors.lastname: Yakimenko
authors.forename: Andrey A
authors.initials: AA
authors.lastname: Tagaev
authors.forename: Anastasia Y
authors.initials: AY
authors.lastname: Ovchinnikova
authors.forename: Arkadiy N
authors.initials: AN
authors.lastname: Murashev
authors.forename: Andrey A
authors.initials: AA
authors.lastname: Kamenskii
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D007473:Ion Channels / Q000187:drug effects*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D054848:Peptaibols; D010455:Peptides / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D007473:Ion Channels; D054848:Peptaibols; D010455:Peptides; C077077:zervamicin IIB; C051145:zervamicin IIA